Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $23 to $28.